Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.90), $0.16 worse than the analyst estimate of ($0.74). Non revenues reported.

"The Company did not report any revenue for the first quarter of 2017 compared to $15.0 million of revenue for the first quarter of 2016, which represented a milestone payment from AbbVie related to the commencement of Phase III studies of elagolix in uterine fibroids.."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.